Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S filed a Form 6-K for June 2022. On June 7, 2022, the biotechnology company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (LPC) for a potential equity financing facility.
Financing and key financial metrics
- The company may elect to sell LPC up to $40.0 million of American Depositary Shares (ADSs) over a 36-month term, subject to contractual conditions and limitations.
- Each ADS represents one ordinary share.
- Regular purchases may generally be up to 50,000 ADSs per business day, increasing to 70,000 ADSs under specified circumstances. LPC is not required to purchase more than $1.5 million in any single regular purchase.
- Purchase prices will be based on the prevailing ADS market price, without a fixed discount. The agreement contains no upper limit on the price per share.
- The company is not obligated to sell any ADSs and controls the timing and amount of sales. It may terminate the agreement at any time without cost or penalty.
- The company must pay LPC a $1.2 million commitment fee within five business days of signing. At its option, the fee may be paid through issuance of 428,572 ordinary shares.
- As of March 31, 2022, unaudited cash and cash equivalents were $31.4 million.
- The filing provides no revenue, profit, margin, operating cash flow, debt, or additional liquidity figures.
Material changes and outlook
- The new purchase agreement provides potential access to up to $40.0 million of additional equity capital, but the filing does not indicate that any ADSs had been sold as of the filing date.
- Management reaffirmed that existing cash, excluding proceeds from the LPC agreement, is expected to fund operating expenses and capital expenditure requirements for at least the next 12 months based on the current scope of activities.
- The company also entered into a registration rights agreement and agreed to file and maintain an effective SEC registration statement covering ADSs issued and sold under the purchase agreement.
Risks, contingencies, and unusual items
- Future funding depends on the company’s election to draw on the facility, market conditions, the ADS share price meeting applicable thresholds, and other contractual conditions.
- Any ADS sales could dilute existing shareholders. Issuing 428,572 ordinary shares to pay the commitment fee would also result in dilution.
- The agreement prohibits the company from entering into a variable-rate transaction while the agreement is in effect.
- The $1.2 million commitment fee is payable regardless of whether the company ultimately sells ADSs, subject to the agreement’s terms.
- The filing does not provide a forecast of revenue, profitability, clinical milestones, or future operating cash needs.
Important facts for investors to verify
- Whether and when Evaxion draws on the LPC facility and the number and price of ADSs sold.
- Whether the $1.2 million commitment fee is paid in cash or through issuance of 428,572 ordinary shares.
- The terms and effectiveness of the SEC registration statement required under the registration rights agreement.
- Subsequent cash balances, operating cash burn, capital requirements, and any changes to the company’s 12-month liquidity assessment.
- The contractual threshold prices, accelerated purchase provisions, and remaining availability under the purchase agreement.